HESTER BIOSCIENCES LTD

For FY 20-21, Ahmedabad-based Hester Biosciences witnessed a revenue generation of Rs 162 crore in the biopharma space, exhibiting a growth of 5 per cent in comparison to the revenue generated in the previous year at Rs 154 crore. In 2020, the Indian Institute of Technology, Guwahati (IIT-G) collaborated with Hester Biosciences to work on the vaccine development against COVID-19, based on recombinant avian paramyxovirus-based vector platform. It signed an agreement towards receiving the developed technology from the ICAR – IVRI, for developing the Brucella Abortus S19 Delta Per vaccine for cattle.